TY - JOUR
T1 - Locoregional control in high-risk neuroblastoma using highly-conformal image-guided radiotherapy, with reduced margins and a boost dose for residual lesions
AU - Samim, Atia
AU - Littooij, Annemieke S.
AU - Peters, Max
AU - de Keizer, Bart
AU - van der Steeg, Alida F.W.
AU - Fajardo, Raquel Dávila
AU - Kraal, Kathelijne C.J.M.
AU - Dierselhuis, Miranda P.
AU - van Eijkelenburg, Natasha K.A.
AU - van Grotel, Martine
AU - Polak, Roel
AU - van de Ven, Cornelis P.
AU - Wijnen, Marc H.W.A.
AU - Seravalli, Enrica
AU - Willemsen-Bosman, Mirjam E.
AU - van Noesel, Max M.
AU - Tytgat, Godelieve A.M.
AU - Janssens, Geert O.
N1 - Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.
PY - 2025/1
Y1 - 2025/1
N2 - INTRODUCTION: Radiotherapy protocols for high-risk neuroblastoma (HR-NBL) vary across international studies. The purpose of this study was to evaluate the locoregional control in a national HR-NBL cohort treated with highly-conformal image-guided radiotherapy (IGRT), using reduced margins, and a boost dose for residual lesions.MATERIALS AND METHODS: Patients treated with radiotherapy as part of first-line HR-NBL treatment between 2015 and 2022 were eligible. To obtain clinical, internal, and planning target volumes, +0.5 cm, 4DCT-based, and + 0.3/0.5 cm margins, respectively, were added to the edited gross tumour volumes. Prescription dose was 21.6/1.8 Gy, followed by 14.4/1.8 Gy for any residual lesions measuring ≥ 1 cm
3 at the time of radiotherapy planning. Intensity-modulated arc therapy was combined with daily cone beam CT-based online patient position verification. Locoregional failure (LRF) rates were compared for the presence of residual lesions < 1 cm
3 vs. ≥ 1 cm
3 (with/without locoregional activity on nuclear- and MRI[diffusion-weighted imaging]-scans) pre-radiotherapy, age at diagnosis, MYCN-status, [
131I]mIBG therapy, response to induction chemotherapy, interval to radiotherapy onset, and metastatic site irradiation.
RESULTS: Among the 77 included patients, 34 had residual lesions (median volume: 10.0 cm
3, IQR 4.8-29.9) with activity visible on 17 nuclear- and 10 MRI-scans. Five-year LRF rate was 7.8 % (95 % confidence interval 1.8-13.8), and not significantly different between those with residual lesions < 1 cm
3 vs. ≥ 1 cm
3 (6.4 % vs. 14.3 %, respectively, p = 0.27), or any of the other variables. All 6 LRFs (2 isolated, 4 combined) occurred < 1.5 years post-radiotherapy.
CONCLUSION: In HR-NBL, IGRT with reduced margins and a boost dose for residual lesions ≥ 1 cm
3 demonstrated excellent locoregional control, comparable to modern literature.
AB - INTRODUCTION: Radiotherapy protocols for high-risk neuroblastoma (HR-NBL) vary across international studies. The purpose of this study was to evaluate the locoregional control in a national HR-NBL cohort treated with highly-conformal image-guided radiotherapy (IGRT), using reduced margins, and a boost dose for residual lesions.MATERIALS AND METHODS: Patients treated with radiotherapy as part of first-line HR-NBL treatment between 2015 and 2022 were eligible. To obtain clinical, internal, and planning target volumes, +0.5 cm, 4DCT-based, and + 0.3/0.5 cm margins, respectively, were added to the edited gross tumour volumes. Prescription dose was 21.6/1.8 Gy, followed by 14.4/1.8 Gy for any residual lesions measuring ≥ 1 cm
3 at the time of radiotherapy planning. Intensity-modulated arc therapy was combined with daily cone beam CT-based online patient position verification. Locoregional failure (LRF) rates were compared for the presence of residual lesions < 1 cm
3 vs. ≥ 1 cm
3 (with/without locoregional activity on nuclear- and MRI[diffusion-weighted imaging]-scans) pre-radiotherapy, age at diagnosis, MYCN-status, [
131I]mIBG therapy, response to induction chemotherapy, interval to radiotherapy onset, and metastatic site irradiation.
RESULTS: Among the 77 included patients, 34 had residual lesions (median volume: 10.0 cm
3, IQR 4.8-29.9) with activity visible on 17 nuclear- and 10 MRI-scans. Five-year LRF rate was 7.8 % (95 % confidence interval 1.8-13.8), and not significantly different between those with residual lesions < 1 cm
3 vs. ≥ 1 cm
3 (6.4 % vs. 14.3 %, respectively, p = 0.27), or any of the other variables. All 6 LRFs (2 isolated, 4 combined) occurred < 1.5 years post-radiotherapy.
CONCLUSION: In HR-NBL, IGRT with reduced margins and a boost dose for residual lesions ≥ 1 cm
3 demonstrated excellent locoregional control, comparable to modern literature.
KW - Abdominal radiotherapy
KW - High-risk neuroblastoma
KW - Highly conformal radiotherapy
KW - Image-guided radiotherapy
KW - Locoregional failure
KW - Pattern of failure
KW - Radiotherapy boost
KW - Residue
KW - Tertiary hospital
KW - Radiotherapy Dosage
KW - Radiotherapy Planning, Computer-Assisted/methods
KW - Radiotherapy, Intensity-Modulated/methods
KW - Humans
KW - Child, Preschool
KW - Infant
KW - Male
KW - Radiotherapy, Conformal/methods
KW - Radiotherapy, Image-Guided/methods
KW - Adolescent
KW - Female
KW - Retrospective Studies
KW - Neuroblastoma/radiotherapy
KW - Child
KW - Neoplasm, Residual/radiotherapy
UR - https://www.scopus.com/pages/publications/85208109793
UR - https://www.mendeley.com/catalogue/1d93346c-42ae-3b7e-8a8e-5b6fb0cebd39/
U2 - 10.1016/j.radonc.2024.110604
DO - 10.1016/j.radonc.2024.110604
M3 - Article
C2 - 39481605
AN - SCOPUS:85208109793
SN - 0167-8140
VL - 202
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 110604
ER -